Previous close | 6.27 |
Open | 6.38 |
Bid | 6.78 x 440000 |
Ask | 6.82 x 420000 |
Day's range | 6.38 - 6.38 |
52-week range | 1.97 - 13.70 |
Volume | |
Avg. volume | 346 |
Market cap | 491.613M |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.48 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 20 Jan 2017 |
1y target est | 30.86 |
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 5, 2024Fireside Chat at 2:00 p.m. Eastern TimeGoldman Sachs Global Healthcare Conference (Miami Beach, FL)Wednesday, June 12, 2024Fireside Chat at 9:20
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) will be presented at the EASL International Liver Congress™ 2024 in Milan, Italy. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for
Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which began trading on Nasdaq today. OZEM is the world's first ETF focused exclusively on the rapidly growing sector of GLP-1 receptor agonists and other weight management drugs.